Research analysts at StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO – Get Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.
Organovo Stock Up 2.8 %
Organovo stock opened at $0.47 on Friday. The company has a market capitalization of $7.15 million, a PE ratio of -0.34 and a beta of 0.62. The firm’s fifty day moving average is $0.50 and its 200 day moving average is $0.70. Organovo has a 12-month low of $0.40 and a 12-month high of $2.05.
Organovo (NASDAQ:ONVO – Get Free Report) last released its quarterly earnings data on Monday, August 5th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.15. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.03 million. Sell-side analysts expect that Organovo will post -0.96 EPS for the current fiscal year.
Institutional Investors Weigh In On Organovo
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Articles
- Five stocks we like better than Organovo
- How to Use the MarketBeat Stock Screener
- Battle of the Retailers: Who Comes Out on Top?
- Find and Profitably Trade Stocks at 52-Week Lows
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Stock Market Sectors: What Are They and How Many Are There?
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.